M3 Anticholinergic Compounds for Topical Hyperhidrosis Treatment
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
There is a need for new muscarinic acetylcholine receptor antagonists to treat various diseases and disorders, as existing agents are inadequate for certain indications.
Innovation Solution
Development of novel compounds and salts of Formula I, which act as muscarinic receptor antagonists, including specific sub-formulae like Formula I-1, I-2, I-3, and I-4, with varying substituents and stereoisomeric forms, for use in pharmaceutical compositions to treat conditions mediated by M3 receptors.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If existing muscarinic antagonists (atropine, scopolamine, homatropine, eucatropine) are used, then some therapeutic effects are achieved, but they are inadequate for certain indications and require development of new agents
Solution Approach 1:
The patent segments the muscarinic receptor antagonism into selective subtypes (M1, M2, M3, M4, M5) and develops compounds with preferential affinity for specific subtypes. This allows different compounds to target specific indications: M1 for neurological disorders, M2 for cardiac conditions, M3 for respiratory and gastrointestinal disorders, thereby resolving the inadequacy of existing non-selective agents for certain indications.
Solution Approach 2:
The patent introduces specific structural modifications at different positions of the tropane core structure to achieve selective binding to different muscarinic receptor subtypes. By optimizing local chemical properties (substituents at positions R1, R2, R3, R4, R5, R6, R7, R8), the compounds achieve subtype-selective antagonism, making them suitable for specific indications while maintaining overall anticholinergic activity.
2Adaptability or versatility
If new muscarinic antagonists are developed to address specific indications, then therapeutic versatility is improved, but the complexity of identifying optimal compounds increases
Solution Approach 1:
The patent develops a universal tropane core structure (Formula I) that can serve multiple functions by varying the substituents. This core structure provides the basic anticholinergic activity while allowing customization for different indications through systematic modification of R1-R8 groups, thereby achieving versatility without excessive complexity.
Solution Approach 2:
The patent systematically varies chemical parameters (substituent types, positions, and configurations at R1-R8) to optimize compound properties for different indications. By changing these parameters in a structured manner, the patent achieves diverse therapeutic applications while maintaining a consistent core structure, balancing versatility with manageable complexity.
Data Source
AI summary
Compounds shown in Formula (I), pharmaceutical compositions, and methods of using related to muscarinic acetylcholine receptors. The compounds herein are typically muscarinic acetylcholine receptor antagonists, such as M3 antagonists, which can be used for treating a variety of disorders, conditions or diseases such as hyperhidrosis.